Search research articles
Contact Us
Filters
Showing results (11-20 of 262) with videos related to
Page
of 27
Sort By:
Current Clinical Pharmacology
|
February 17, 2010
Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas
Luca Arcaini, Raffaele Bruno
Leukemia & Lymphoma
|
September 29, 2021
The double significance of idelalisib immune-related toxicity
Michele Merli, Francesco Passamonti, Luca Arcaini
Therapeutic Advances in Hematology
|
April 8, 2016
Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?
Barbara Vannata, Luca Arcaini, Emanuele Zucca
Blood
|
March 19, 2016
Splenic marginal zone lymphoma: from genetics to management
Luca Arcaini, Davide Rossi, Marco Paulli
British Journal of Haematology
|
November 1, 2020
Antiviral prophylaxis for hepatitis B carriers affected by diffuse large B cell lymphoma: a matter of survival
Valentina Zuccaro, Raffaele Bruno, Luca Arcaini
British Journal of Haematology
|
August 18, 2023
Deciphering molecular complexity of HCV-associated lymphoproliferation
Michele Merli, Francesco Passamonti, Luca Arcaini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2022
Reply to M. Shibusawa et al
Stefano Luminari, Luca Arcaini, Massimo Federico
Expert Opinion on Pharmacotherapy
|
June 14, 2021
Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma
Chiara Cavalloni, Marzia Varettoni, Sara Rattotti, et al.
Thescientificworldjournal
|
August 25, 2012
Prognostic assessment in patients with indolent B-cell lymphomas
Luca Arcaini, Sara Rattotti, Manuel Gotti, et al.
World Journal of Gastroenterology
|
October 28, 2016
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma
Michele Merli, Giuseppe Carli, Luca Arcaini, et al.
Page
of 27
Search research articles
Search
Showing results (11-20 of 262) with videos related to
Sort By:
Page
of 27
Current Clinical Pharmacology
|
February 17, 2010
Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas
Luca Arcaini, Raffaele Bruno
Leukemia & Lymphoma
|
September 29, 2021
The double significance of idelalisib immune-related toxicity
Michele Merli, Francesco Passamonti, Luca Arcaini
Therapeutic Advances in Hematology
|
April 8, 2016
Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?
Barbara Vannata, Luca Arcaini, Emanuele Zucca
Blood
|
March 19, 2016
Splenic marginal zone lymphoma: from genetics to management
Luca Arcaini, Davide Rossi, Marco Paulli
British Journal of Haematology
|
November 1, 2020
Antiviral prophylaxis for hepatitis B carriers affected by diffuse large B cell lymphoma: a matter of survival
Valentina Zuccaro, Raffaele Bruno, Luca Arcaini
British Journal of Haematology
|
August 18, 2023
Deciphering molecular complexity of HCV-associated lymphoproliferation
Michele Merli, Francesco Passamonti, Luca Arcaini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2022
Reply to M. Shibusawa et al
Stefano Luminari, Luca Arcaini, Massimo Federico
Expert Opinion on Pharmacotherapy
|
June 14, 2021
Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma
Chiara Cavalloni, Marzia Varettoni, Sara Rattotti, et al.
Thescientificworldjournal
|
August 25, 2012
Prognostic assessment in patients with indolent B-cell lymphomas
Luca Arcaini, Sara Rattotti, Manuel Gotti, et al.
World Journal of Gastroenterology
|
October 28, 2016
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma
Michele Merli, Giuseppe Carli, Luca Arcaini, et al.
Page
of 27